Dose-dependent modulation of apoptotic processes by fluoxetine in maturing neuronal cells: An in vitro study

World Journal of Biological Psychiatry

Volumn 12, Issue 2, 2011, Pages 89-98

  Schaz, Ulrike ^a   Föhr, Karl J ^a   Liebau, Stefan ^a   Fulda, Simone ^b   Koelch, Michael ^a   Fegert, Joerg M ^a   Boeckers, Tobias M ^a   Ludolph, Andrea G ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Brain development; Depression; Fluoxetine; GABA agonism; NMDA antagonism

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; FLUOXETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN TRANSPORTER; N METHYLASPARTIC ACID; SEROTONIN UPTAKE INHIBITOR;

APOPTOSIS; ARTICLE; ASSAY; BRAIN; BRAIN CORTEX; CELL MATURATION; CELL STRAIN HEK293; CELL VIABILITY; CORPUS STRIATUM; DOSE RESPONSE; ELECTROPHYSIOLOGY; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCEPHALON; NERVE CELL; PROTEIN EXPRESSION; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; RAT;

ANIMALS; APOPTOSIS; BRAIN; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FLUOXETINE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; N-METHYLASPARTATE; NEURONS; RATS; RECEPTORS, GABA; SEROTONIN UPTAKE INHIBITORS;

EID: 79960105481     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.506927     Document Type: Article

References (54)

1. Andrade C, Bhakta SG, Singh NM. 2006. Controversy revisted: Selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry 7:251-260. (Pubitemid 44650535)
2. Aznavour N, Rbah L, Riad M, Reilhac A, Costes N, Descarries L, Zimmer L. 2006. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. Neuroimage 33:834-842. (Pubitemid 44584760)
3. Bertilsson L, Dahl ML, Tybring G. 1997. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 391(Suppl):14-21. (Pubitemid 27333214)
4. Bock N, Quentin DJ, Hüther G, Moll GH, Banaschewski T, Rothenberger A. 2005. Very eraly treatment with fluoxetine and reboxetine causing long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of rats. World J Biol Psychiatry 6:107-112. (Pubitemid 40895134)
5. Boeckers TM, Liedtke T, Spilker C, Dresbach T, Bockmann J, Kreutz, MR, Gundelfi nger ED. 2005. C-terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/ Shank2 and Pro-SAP2/Shank3. J Neurochem 92:519-524. (Pubitemid 40189455)
6. Bolo NR, Hode Y, Nedelec J-F, Leine E, Wagmer G, Macher J-P. 2000. Brain pharmacokinetics and tissue distribution in vivo of fl uvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23:428-448.
7. Chiou SH, Chen SJ, Peng CH, Chang YL, Ku HH, Hsu WM, et al. 2006. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 343:391-400.
8. Doetsch F, Caille I, Lim DA, Garcia-Verdugo J, Avarez-Buylla A. 1999. Subvetricular zone astocytes are neural stem cells in the adult mammalian brain. Cell 97:703-716. (Pubitemid 29278045)
9. Dresbach T, Hempelmann A, Spilker C, tom Dieck S, Altroch WD, Zuschratter W, et al. 2003. Functional regions of the presynaptic cytomatrix protein bassoon: signifi cance for synaptic targeting and cytomatrix anchoring. Mol Cell Neurosci 23:279-291. (Pubitemid 36703162)
10. Duman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606. (Pubitemid 27306570)
11. Fossati P, Radtchenko A, Boyer P. 2004. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharmacol 14:S503-510. (Pubitemid 39531612)
12. Fuchs E, Cz é h F, Kole MHP, Michaelis T, Lucassen PJ. 2004. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 14:S481-490. (Pubitemid 39531609)
13. Fulda S, Friesen C, Los M, Scaffi di C, Mier W, Benedict M, et al. 1997. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956-4964. (Pubitemid 27469008)
14. Goslin K, Banker G. 1989. Experimental observations on the development of polarity by hippocampal neurons in culture. J Cell Biol 108:1507-1516. (Pubitemid 19097054)
15. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74.
16. Henkel AW, Sperling W, Rotter A, Reulbach U, REichardt C, Bönsch D, et al. 2008. Antidepressant drugs modulate growth factors in cultured cells. BMC Pharmacol 8:6.
17. Henry ME, Schnidt ME, Hennen J, Villafuerte RA, Butman ML, Tram P, et al. 2005. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology 30:1576-1583. (Pubitemid 41153130)
18. Horschitz S, Hummerich R, Schloss P. 2001. Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuropharm Neurotox 12: 2181-2184. (Pubitemid 32646268)
19. Ikonomidou C. 2009. Triggers of apoptosis in the immature brain. Brain Develop 31:448-492.
20. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, et al. 1999. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70-74. (Pubitemid 29044848)
21. Ishimaru MJ, Ikonomidou C, Tenkova TI, Der TC, Dirkanian K, Sesma MA, Olney JW. 1999. Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain. J Comp Neurol 408:461-476. (Pubitemid 29211175)
22. Johannsen S, Duning K, Pavanst ä dt H, Kremerskothen J, Böckers TM. 2008. Temporal spatial expression and novel biochemical properties of the memory-related protein KIPRA. Neuroscience 155:1165-1173.
23. Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. 1993. Human brain fluoxetine concentration. J Neuropsychol 5:322-329.
24. Kielbasa W, Kalvass JC, Stratford R. 2009. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos 37: 137-142.
25. Koch JM, Kell S, Aldenhoff JB. 2003. Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability. J Psychiatr Res 37:53-59. (Pubitemid 35449771)
26. Kosten TA, Galloway MP, Duman RS, Russell DS, D ' Sa C. 2008. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 33:1545-1558. (Pubitemid 351684697)
27. Laming PR, Kimelberg H, Robinson S, Salm A, Hawrylak N, M ü ller C, et al. 2000. Neuronal-glial interactions and behaviour. Neurosci Biobehav Rev 24:295-340. (Pubitemid 30227249)
28. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. 2005. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines. J Mol Neurosci 27:29-42.
29. Ling Z, Pieri SC, Carvey PM. 1996. Comparison of the neurotoxicity of dehydroxyphenyl-alanine stereaoisomers in cultured dopamine neurons. Clin Neuropharmacol 19:360-365. (Pubitemid 26250120)
30. Ludolph AG, Schaz U, Storch A, Liebau S, Fegert JM, Böckers TM. 2006. No neurotoxic but neuroprotective effects of methylphenidate in primary mesencephalic cultures. J Neural Transm 113:1927-1934. (Pubitemid 44749635)
31. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weight HU, et al. 2010. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol 160:283-291.
32. Malberg JE, Duman RS. 2003. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28:1562-1571. (Pubitemid 41070856)
33. Mallei A, Shi B, Mocchetti I. 2002. Antidepresant treatments induce the expression of basic fi broblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 61: 1017-1024. (Pubitemid 34441766)
34. Manev H, Uz T, Manev R. 2003. Glia as a putative target for antidepressant treatments. J Affect Disord 75:59-64. (Pubitemid 36645020)
35. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F, Pierre M. 2004. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 24:207-216. (Pubitemid 41359148)
36. Molliver ME. 1987. Serotonergic neuronal systems: what their anatomical organization tells us about function. J Clin Psychopharmacol 7:3-23S.
37. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and fl ow cytometry. J Immunol Methods 139:271-279.
38. Rajkowska G. 2000a. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48: 766-777.
39. Rajkowska G. 2000b. Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res 126:397-412. (Pubitemid 35461302)
40. Robinson RT, Drafts BC, Fisher JL. 2003. Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. J Pharmacol Exp Ther 304:978-984. (Pubitemid 36254408)
41. Rubenstein JLR. 1998. Development of serotoninergic neurons and their projections. Biol Psychiatry 44:145-150.
42. Sanacora G, Saricicik A. 2007. GABAergic contributions to the pathophysiology if depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6:127-140. (Pubitemid 46681773)
43. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809. (Pubitemid 36962615)
44. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, et al. 2003. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212-3219. (Pubitemid 36858017)
45. Seri B, Garcia-Verugo JM, McEwen BS, Alvarez-Buylla A. 2001. Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci 21:7153-7160. (Pubitemid 32846963)
46. Schuster C, Fernbach N, Rix U, Superti-Furga G. Holy M, Freissmuth M, et al. 2007. Selective serotonin reuptake inhibitors-A new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol 74:1424-1435. (Pubitemid 47445448)
47. Shaw G. Morse S, Ararat M, Graham FL. 2002. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB 16:968-971.
48. Sheline YI, Gado MH, Kraemer HC. 2003. Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516-1518. (Pubitemid 41070930)
49. Storch A, Burkhardt K, Ludolph AC, Schwarz J. 2000. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem 75:2259-2269.
50. Szasz B, Mike A, Karoly R, Gerevich Z, Illes P, Vizi ES. 2007. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry 62:1303-1309. (Pubitemid 350060896)
51. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. 2006. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62:863-870. (Pubitemid 44521435)
52. Wong ML, Licinio J. 2001. Research and treatment approaches to depression. Nat Rev Neurosci 2:243-251.
53. Ye Z-Y, Zhou K-Q, Xu T-L, Zhou J-N. 2008. Fluoxetine potentiates GABAergic IPSCs in rat hippocampal neurons. Neurosci Lett 442:24-29.
54. Zusso M, Debetto P, Guidolin D, Giusti P. 2004. Cerebellar granular cell cultures as an in vitro model for antidepressant drug-induced neurogenesis. Crit Rev Neurobiol 16:59-65. (Pubitemid 39586903)